IP Library Patent Application 13814330
Patent Application
App. No. 13/814,330

PHARMACEUTICAL PREPARATION FOR CONTROLLING WATER-SOLUBLE DRUG RELEASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/814,330
Abstract

A solid formulation comprising a water-soluble drug and a hardly water-soluble pharmaceutically-acceptable solid substance, which comprises silicone as a carrier, wherein the silicone formulation can exhibit an excellent controlled-release of the water-soluble drug.

Claims (14)

1 . A parenteral solid formulation comprising a water-soluble drug and a hardly water-soluble pharmaceutically-acceptable solid substance, which comprises silicone as a carrier.

2 . The parenteral solid formulation of claim 1 wherein the hardly water-soluble substance is low substituted hydroxypropylcellulose, partly pregelatinized starch, crospovidone, croscarmellose sodium, myristic acid, cholesterol and/or saccharin.

3 . The parenteral solid formulation of claim 1 wherein the hardly water-soluble substance is low substituted hydroxypropylcellulose and/or cholesterol.

4 . The parenteral solid formulation of claim 1 wherein the hardly water-soluble substance is contained in 3 to 35% by weight per the whole weight of the formulation.

5 . The parenteral solid formulation of claim 1 wherein the silicone is contained in 55% or more by weight per the whole weight of the formulation.

6 . The parenteral solid formulation of claim 1 further comprising a water-soluble additive agent.

7 . The parenteral solid formulation of claim 6 wherein the water-soluble additive agent is sodium chloride, glucose, mannitol, lactose, glycine, sodium cholate, sodium desoxycholate and/or sodium glycocholate.

8 . The parenteral solid formulation of claim 6 wherein the water-soluble additive agent is sodium chloride and/or sodium desoxycholate.

9 . The parenteral solid formulation of claim 8 wherein the hardly water-soluble substance is low substituted hydroxypropylcellulose, and the water-soluble additive agent is sodium chloride.

10 . The parenteral solid formulation of claim 8 wherein the hardly water-soluble substance is cholesterol, and the water-soluble additive agent is sodium chloride and sodium desoxycholate.

11 . The parenteral solid formulation of claim 1 wherein the total weight of the water-soluble drug, the hardly water-soluble substance and the optional water-soluble additive agent is 10 to 40% per the whole weight of the formulation, provided that the total weight of the water-soluble drug and the water-soluble additive agent is not more than 35% per the whole weight of the formulation.

12 . The parenteral solid formulation of claim 1 comprising essentially a water-soluble drug, a pharmaceutically acceptable hardly water-soluble solid substance, and an optional water-soluble additive agent, and which comprises silicone as a carrier.

13 . The parenteral solid formulation of claim 1 which is a matrix formulation.

14 . The parenteral solid formulation of claim 1 which is an implantable formulation.

Assignments (2)
CHANGE OF NAME Recorded Nov 17, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034255/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2013
From: MAEDA, MIHO
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 029757/0677 →